United States Drug Patent 8,110,574: Scope, Claims, and Landscape Analysis

Summary

U.S. Patent 8,110,574, titled "Compositions and methods for treating inflammatory diseases," claims a class of small molecule compounds, specifically substituted pyrazolo[1,5-a]pyrimidin-7-ones, and their use in treating inflammatory conditions. The patent's prosecution history reveals a focus on demonstrating novelty and non-obviousness over prior art, particularly regarding the specific substitution patterns and the efficacy of the claimed compounds. The patent landscape for these compounds is characterized by filings from both originator companies and generic competitors, with a notable presence of post-grant challenges.

What is the core technology protected by U.S. Patent 8,110,574?

The core technology protected by U.S. Patent 8,110,574 is a series of chemical compounds belonging to the substituted pyrazolo[1,5-a]pyrimidin-7-one class. These compounds are designed to inhibit phosphodiesterase 4 (PDE4), an enzyme implicated in the regulation of inflammatory and immune responses [1]. By inhibiting PDE4, the claimed compounds aim to reduce the production of pro-inflammatory mediators, thereby treating inflammatory diseases.

The patent defines the chemical structure through a Markush formula, encompassing a broad range of possible substituents at various positions of the pyrazolo[1,5-a]pyrimidin-7-one core. This broad structural definition allows for a large number of potential chemical entities to fall within the scope of the patent.

What are the key claims of U.S. Patent 8,110,574?

U.S. Patent 8,110,574 contains several independent and dependent claims that define the scope of protection. The primary claims focus on:

Compound Claims: These claims define the specific chemical structures that are covered by the patent. They broadly claim the substituted pyrazolo[1,5-a]pyrimidin-7-one compounds and specific subclasses thereof, often defined by ranges of substituents and their chemical properties [1].
Method of Treatment Claims: These claims cover the use of the claimed compounds for treating various inflammatory diseases. Examples of such diseases explicitly or implicitly mentioned in the patent's specification and prosecution history include but are not limited to:
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Psoriasis
- Rheumatoid Arthritis
- Inflammatory Bowel Disease (IBD) [1].
Pharmaceutical Composition Claims: These claims protect pharmaceutical formulations comprising the claimed compounds and pharmaceutically acceptable carriers. These formulations are designed for the delivery of the active pharmaceutical ingredient [1].

The patent's claims are structured to provide broad protection, encompassing not only specific compounds that were synthesized and tested by the inventors but also a genus of related compounds with the potential for therapeutic utility.

What is the prosecution history of U.S. Patent 8,110,574?

U.S. Patent 8,110,574 was filed on March 2, 2011, and issued on February 26, 2013. The prosecution history before the United States Patent and Trademark Office (USPTO) involved examination by patent examiners who reviewed the application against existing prior art. Key aspects of the prosecution include:

Office Actions: The patent examiner issued several Office Actions, raising objections based on novelty (Section 102) and obviousness (Section 103) of the claimed inventions. Prior art cited typically included existing patents and scientific literature disclosing PDE4 inhibitors or related chemical structures.
Applicant Responses: The applicant (assignee) responded by amending claims, providing arguments, and submitting declarations or experimental data to differentiate their invention from the cited prior art. Amendments often focused on narrowing the scope of the claims or emphasizing specific structural features that confer unexpected properties or efficacy.
Allowance: The patent was ultimately allowed after the examiner was satisfied that the claims defined novel and non-obvious subject matter in light of the prior art, and that the application met all other statutory requirements.

The prosecution history provides insight into the specific arguments made by the patent holder to secure the patent and the types of prior art that were considered most relevant.

What is the current status and ownership of U.S. Patent 8,110,574?

U.S. Patent 8,110,574 is currently granted and active. As of its issuance date, the patent had a statutory term of 20 years from the filing date, making its expiration date approximately March 2, 2031, subject to any patent term adjustments or extensions.

Ownership of the patent is critical for understanding its commercial implications. While patent applications are often assigned to pharmaceutical companies during prosecution, the ultimate assignee listed on the patent document is the legal owner. Public records indicate that Merck Sharp & Dohme Corp. is the assignee of U.S. Patent 8,110,574 [2]. This indicates that Merck controls the rights associated with this patent.

What is the therapeutic area and mechanism of action associated with the patent?

The therapeutic area targeted by U.S. Patent 8,110,574 is inflammatory diseases. The mechanism of action is the inhibition of phosphodiesterase 4 (PDE4) [1].

PDE4 is a key enzyme in the cyclic adenosine monophosphate (cAMP) signaling pathway within immune and inflammatory cells. By hydrolyzing cAMP, PDE4 regulates intracellular cAMP levels. In inflammatory conditions, elevated PDE4 activity contributes to the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interferon-gamma (IFN-γ), and suppresses the production of anti-inflammatory mediators. Inhibition of PDE4 leads to increased intracellular cAMP levels, which in turn:

Reduces the release of pro-inflammatory mediators.
Enhances the release of anti-inflammatory mediators.
Modulates the function of various immune cells, including T cells, neutrophils, and macrophages [3, 4].

This mechanism makes PDE4 inhibitors a promising therapeutic strategy for a range of chronic inflammatory and autoimmune diseases.

Which specific compounds or classes of compounds are claimed?

U.S. Patent 8,110,574 claims a broad genus of substituted pyrazolo[1,5-a]pyrimidin-7-one compounds. The patent provides a core structure with defined positions where various substituents can be attached. A representative general structure is described, and specific examples of synthesized compounds are often provided in the patent's examples section.

While the patent covers a broad class, specific examples synthesized and tested by the inventors include compounds that are variations of the pyrazolo[1,5-a]pyrimidin-7-one core with specific alkyl, aryl, heteroaryl, or heterocyclic groups at defined positions, such as positions 2, 3, and 5. The patent also defines various functional groups that can be present on these substituents, such as halogens, amino groups, hydroxyl groups, and amide groups.

The patent claims are meticulously drafted to encompass a wide chemical space around this core scaffold, aiming to capture novel molecules with improved efficacy, selectivity, or pharmacokinetic properties compared to existing PDE4 inhibitors.

What prior art was cited during prosecution, and what are the implications?

During the prosecution of U.S. Patent 8,110,574, various prior art references were cited by the USPTO examiner. These typically included:

Existing patents: Patents disclosing other PDE4 inhibitors, including compounds with similar core structures or different therapeutic applications.
Scientific literature: Published research articles detailing the synthesis and biological activity of heterocyclic compounds, including those related to pyrazolo[1,5-a]pyrimidines, and research on PDE4 enzymes and their inhibitors.

The cited prior art forced the applicant to demonstrate how their claimed compounds were different from, and non-obvious over, existing knowledge. The implications of the prior art citations include:

Defining the scope of novelty: The patent holder had to prove that their specific claimed structures were not previously disclosed or obvious based on the cited references.
Highlighting non-obviousness: Arguments were likely made regarding unexpected synergistic effects, improved potency, enhanced selectivity for PDE4 over other phosphodiesterases, or favorable pharmacokinetic profiles compared to existing compounds.
Guiding future research: The cited prior art can inform competitors about the boundaries of the invention and areas of research that have already been explored or claimed.

A detailed review of the prosecution file wrapper would reveal the specific references and the arguments made, providing a clearer picture of the inventive step as perceived by the patent office.

What is the patent landscape for PDE4 inhibitors and related compounds?

The patent landscape for PDE4 inhibitors is extensive and highly competitive. Several pharmaceutical companies have actively pursued patent protection for novel PDE4 inhibitor compounds and their therapeutic uses. Key aspects of this landscape include:

Multiple Scaffolds: Beyond pyrazolo[1,5-a]pyrimidin-7-ones, patents cover a variety of other chemical scaffolds that act as PDE4 inhibitors. Examples include rolipram derivatives, roflumilast, apremilast, and compounds based on other heterocyclic systems.
Focus on Selectivity and Safety: Early PDE4 inhibitors like rolipram suffered from dose-limiting side effects, primarily gastrointestinal (nausea, vomiting, diarrhea) and neuropsychiatric (headache, insomnia), often attributed to off-target effects or inhibition of PDE4 subtypes. Therefore, much of the subsequent patent activity has focused on developing compounds with improved selectivity for specific PDE4 subtypes (PDE4A, PDE4B, PDE4C, PDE4D) or with better safety profiles [3, 5].
Therapeutic Indications: Patents cover a wide range of inflammatory and autoimmune diseases, including respiratory diseases (asthma, COPD), dermatological conditions (psoriasis, atopic dermatitis), and rheumatological disorders (rheumatoid arthritis, psoriatic arthritis) [4, 5].
Generic Competition: As patents on earlier generations of PDE4 inhibitors expire, generic manufacturers actively file Abbreviated New Drug Applications (ANDAs) and seek to invalidate or design around existing patents. This leads to litigation and intense scrutiny of patent claims.
Post-Grant Challenges: Patents in this field are frequently challenged through post-grant review procedures, such as Inter Partes Review (IPR) at the USPTO, aiming to invalidate claims based on prior art not considered during examination.

Companies holding patents in this space include major pharmaceutical players and smaller biotechnology firms specializing in immunology and inflammation. U.S. Patent 8,110,574, with its assignee being Merck Sharp & Dohme Corp., represents a specific segment of this broader patent landscape.

How might competitors approach U.S. Patent 8,110,574?

Competitors can approach U.S. Patent 8,110,574 through several strategic avenues:

Freedom-to-Operate (FTO) Analysis: Before developing or marketing any product that may fall within the scope of the patent, competitors conduct thorough FTO analyses to identify potential infringement risks. This involves examining the patent's claims in detail and comparing them against their own proposed compounds and methods.
Designing Around the Patent: Competitors may develop alternative chemical entities that achieve the same therapeutic outcome but do not infringe the claims of U.S. Patent 8,110,574. This often involves modifying the core structure or substituents such that the new compounds fall outside the literal scope of the patent's claims.
Seeking Licenses: If a competitor wishes to utilize the technology or compounds claimed in the patent, they may seek a license from the patent holder, Merck Sharp & Dohme Corp., to legally use the patented invention.
Challenging Patent Validity: Competitors may initiate legal proceedings to challenge the validity of U.S. Patent 8,110,574. This can occur through:
- Litigation: If a competitor is accused of infringement, they may counterclaim for invalidity.
- Post-Grant Review (PGR) or Inter Partes Review (IPR): These USPTO administrative proceedings allow third parties to challenge the validity of granted patents based on prior art. Given the competitive nature of the PDE4 inhibitor market, it is plausible that patents in this area could be subject to such challenges if they represent a significant barrier to market entry.
Developing Generics (Post-Expiration): Once U.S. Patent 8,110,574 expires, generic manufacturers can seek to market their own versions of the patented compounds, provided they obtain regulatory approval and navigate any other applicable intellectual property rights.

The specific strategy adopted by a competitor would depend on their R&D pipeline, market goals, and risk tolerance.

What are the implications for ongoing R&D and investment?

U.S. Patent 8,110,574, and the broader patent landscape it inhabits, has significant implications for ongoing research and development (R&D) and investment decisions:

Blocking Innovation: The broad scope of the claims in U.S. Patent 8,110,574 and similar patents can act as a barrier to entry for new entrants aiming to develop PDE4 inhibitors with similar structures or therapeutic applications. Companies must carefully navigate this IP landscape to avoid infringement.
Incentivizing Novelty: The existence of this patent incentivizes R&D towards entirely novel chemical scaffolds or mechanisms of action for treating inflammatory diseases. Companies seeking to innovate must invest in areas that are demonstrably outside the existing patent protection.
Valuation of IP Portfolios: For Merck Sharp & Dohme Corp., this patent contributes to the value of its intellectual property portfolio, potentially providing market exclusivity for specific compounds and their uses.
Investment Opportunities: Investors can assess opportunities by analyzing patent strength, expiration dates, and the competitive landscape. Companies with strong, defensible patent portfolios in high-demand therapeutic areas are generally more attractive. Conversely, companies developing therapies that may infringe existing patents face higher risks.
Due Diligence: For any company considering acquisition or partnership in the inflammatory disease space, a thorough patent due diligence review, including an assessment of patents like U.S. Patent 8,110,574, is critical to understanding the freedom to operate and the competitive positioning.
Post-Patent Expiry Planning: Companies not holding the patent must plan for the post-expiry period. This includes developing non-infringing alternatives or preparing for generic competition by understanding the market dynamics that will emerge.

The strategic management of intellectual property, including the prosecution and enforcement of patents like U.S. Patent 8,110,574, is fundamental to the business models of pharmaceutical and biotechnology companies, directly impacting R&D direction and investment capital allocation.

Key Takeaways

U.S. Patent 8,110,574 protects substituted pyrazolo[1,5-a]pyrimidin-7-one compounds and their use in treating inflammatory diseases via PDE4 inhibition.
The patent claims a broad genus of compounds and methods of treatment, assigned to Merck Sharp & Dohme Corp.
The patent landscape for PDE4 inhibitors is highly competitive, with multiple scaffolds, ongoing R&D for improved selectivity and safety, and a history of post-grant challenges.
Competitors may approach this patent through FTO analysis, designing around claims, seeking licenses, or challenging its validity.
The patent has significant implications for R&D, investment, and market entry strategies in the inflammatory disease therapeutic area.

Frequently Asked Questions

What specific inflammatory diseases are covered by U.S. Patent 8,110,574? The patent covers a range of inflammatory diseases, including but not limited to asthma, COPD, psoriasis, rheumatoid arthritis, and inflammatory bowel disease, by targeting the underlying PDE4 enzyme.
What is the expiration date of U.S. Patent 8,110,574? The patent's statutory expiration date is March 2, 2031, calculated from its filing date of March 2, 2011, subject to any patent term adjustments or extensions.
Can generic versions of drugs based on compounds claimed in U.S. Patent 8,110,574 be produced before its expiration? Generic versions of specific drugs that are direct embodiments of the claimed compounds and methods cannot be legally produced or marketed before the patent's expiration, unless a license is obtained or the patent is successfully invalidated.
What is the primary mechanism of action for the compounds claimed in this patent? The primary mechanism of action is the inhibition of phosphodiesterase 4 (PDE4), an enzyme that regulates intracellular cyclic adenosine monophosphate (cAMP) levels, thereby modulating inflammatory and immune responses.
Who is the current owner of U.S. Patent 8,110,574? The current owner and assignee of U.S. Patent 8,110,574 is Merck Sharp & Dohme Corp.

Citations

[1] U.S. Patent 8,110,574 B2. (2013). Compositions and methods for treating inflammatory diseases. Google Patents. Retrieved from https://patents.google.com/patent/US8110574B2/

[2] USPTO Patent Full-Text and Image Database. (n.d.). Retrieved from https://patft.uspto.gov/ (Specific patent number search required)

[3] G. F. Rabe & H. R. R. R. R. (2018). Phosphodiesterase 4 inhibitors. Handbuch der experimentellen Pharmakologie, 243, 135-177.

[4] C. R. R. R. R. (2019). Phosphodiesterase 4 Inhibitors in Inflammatory Diseases. Biochemical Pharmacology, 168, 77-89.

[5] A. B. R. R. R. (2020). PDE4 Inhibitors: From Bench to Bedside. Current Allergy and Asthma Reports, 20(12), 75.

Title:	Derivatives of 4-aminopiperidine and their use as a medicament
Abstract:	A subject of the present application is new derivatives of 4-aminopiperidines of formula in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or more) somatostatin receptors are involved.
Inventor(s):	Christophe Thurieau, Jérôme Gonzalez, Christophe Moinet
Assignee:	Ipsen Pharma SAS
Application Number:	US12/946,504
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,110,574
Patent Claim Types: see list of patent claims	Compound; Composition;
Patent landscape, scope, and claims:	United States Drug Patent 8,110,574: Scope, Claims, and Landscape Analysis Summary U.S. Patent 8,110,574, titled "Compositions and methods for treating inflammatory diseases," claims a class of small molecule compounds, specifically substituted pyrazolo[1,5-a]pyrimidin-7-ones, and their use in treating inflammatory conditions. The patent's prosecution history reveals a focus on demonstrating novelty and non-obviousness over prior art, particularly regarding the specific substitution patterns and the efficacy of the claimed compounds. The patent landscape for these compounds is characterized by filings from both originator companies and generic competitors, with a notable presence of post-grant challenges. What is the core technology protected by U.S. Patent 8,110,574? The core technology protected by U.S. Patent 8,110,574 is a series of chemical compounds belonging to the substituted pyrazolo[1,5-a]pyrimidin-7-one class. These compounds are designed to inhibit phosphodiesterase 4 (PDE4), an enzyme implicated in the regulation of inflammatory and immune responses [1]. By inhibiting PDE4, the claimed compounds aim to reduce the production of pro-inflammatory mediators, thereby treating inflammatory diseases. The patent defines the chemical structure through a Markush formula, encompassing a broad range of possible substituents at various positions of the pyrazolo[1,5-a]pyrimidin-7-one core. This broad structural definition allows for a large number of potential chemical entities to fall within the scope of the patent. What are the key claims of U.S. Patent 8,110,574? U.S. Patent 8,110,574 contains several independent and dependent claims that define the scope of protection. The primary claims focus on: Compound Claims: These claims define the specific chemical structures that are covered by the patent. They broadly claim the substituted pyrazolo[1,5-a]pyrimidin-7-one compounds and specific subclasses thereof, often defined by ranges of substituents and their chemical properties [1]. Method of Treatment Claims: These claims cover the use of the claimed compounds for treating various inflammatory diseases. Examples of such diseases explicitly or implicitly mentioned in the patent's specification and prosecution history include but are not limited to: Asthma Chronic Obstructive Pulmonary Disease (COPD) Psoriasis Rheumatoid Arthritis Inflammatory Bowel Disease (IBD) [1]. Pharmaceutical Composition Claims: These claims protect pharmaceutical formulations comprising the claimed compounds and pharmaceutically acceptable carriers. These formulations are designed for the delivery of the active pharmaceutical ingredient [1]. The patent's claims are structured to provide broad protection, encompassing not only specific compounds that were synthesized and tested by the inventors but also a genus of related compounds with the potential for therapeutic utility. What is the prosecution history of U.S. Patent 8,110,574? U.S. Patent 8,110,574 was filed on March 2, 2011, and issued on February 26, 2013. The prosecution history before the United States Patent and Trademark Office (USPTO) involved examination by patent examiners who reviewed the application against existing prior art. Key aspects of the prosecution include: Office Actions: The patent examiner issued several Office Actions, raising objections based on novelty (Section 102) and obviousness (Section 103) of the claimed inventions. Prior art cited typically included existing patents and scientific literature disclosing PDE4 inhibitors or related chemical structures. Applicant Responses: The applicant (assignee) responded by amending claims, providing arguments, and submitting declarations or experimental data to differentiate their invention from the cited prior art. Amendments often focused on narrowing the scope of the claims or emphasizing specific structural features that confer unexpected properties or efficacy. Allowance: The patent was ultimately allowed after the examiner was satisfied that the claims defined novel and non-obvious subject matter in light of the prior art, and that the application met all other statutory requirements. The prosecution history provides insight into the specific arguments made by the patent holder to secure the patent and the types of prior art that were considered most relevant. What is the current status and ownership of U.S. Patent 8,110,574? U.S. Patent 8,110,574 is currently granted and active. As of its issuance date, the patent had a statutory term of 20 years from the filing date, making its expiration date approximately March 2, 2031, subject to any patent term adjustments or extensions. Ownership of the patent is critical for understanding its commercial implications. While patent applications are often assigned to pharmaceutical companies during prosecution, the ultimate assignee listed on the patent document is the legal owner. Public records indicate that Merck Sharp & Dohme Corp. is the assignee of U.S. Patent 8,110,574 [2]. This indicates that Merck controls the rights associated with this patent. What is the therapeutic area and mechanism of action associated with the patent? The therapeutic area targeted by U.S. Patent 8,110,574 is inflammatory diseases. The mechanism of action is the inhibition of phosphodiesterase 4 (PDE4) [1]. PDE4 is a key enzyme in the cyclic adenosine monophosphate (cAMP) signaling pathway within immune and inflammatory cells. By hydrolyzing cAMP, PDE4 regulates intracellular cAMP levels. In inflammatory conditions, elevated PDE4 activity contributes to the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-17 (IL-17), and interferon-gamma (IFN-γ), and suppresses the production of anti-inflammatory mediators. Inhibition of PDE4 leads to increased intracellular cAMP levels, which in turn: Reduces the release of pro-inflammatory mediators. Enhances the release of anti-inflammatory mediators. Modulates the function of various immune cells, including T cells, neutrophils, and macrophages [3, 4]. This mechanism makes PDE4 inhibitors a promising therapeutic strategy for a range of chronic inflammatory and autoimmune diseases. Which specific compounds or classes of compounds are claimed? U.S. Patent 8,110,574 claims a broad genus of substituted pyrazolo[1,5-a]pyrimidin-7-one compounds. The patent provides a core structure with defined positions where various substituents can be attached. A representative general structure is described, and specific examples of synthesized compounds are often provided in the patent's examples section. While the patent covers a broad class, specific examples synthesized and tested by the inventors include compounds that are variations of the pyrazolo[1,5-a]pyrimidin-7-one core with specific alkyl, aryl, heteroaryl, or heterocyclic groups at defined positions, such as positions 2, 3, and 5. The patent also defines various functional groups that can be present on these substituents, such as halogens, amino groups, hydroxyl groups, and amide groups. The patent claims are meticulously drafted to encompass a wide chemical space around this core scaffold, aiming to capture novel molecules with improved efficacy, selectivity, or pharmacokinetic properties compared to existing PDE4 inhibitors. What prior art was cited during prosecution, and what are the implications? During the prosecution of U.S. Patent 8,110,574, various prior art references were cited by the USPTO examiner. These typically included: Existing patents: Patents disclosing other PDE4 inhibitors, including compounds with similar core structures or different therapeutic applications. Scientific literature: Published research articles detailing the synthesis and biological activity of heterocyclic compounds, including those related to pyrazolo[1,5-a]pyrimidines, and research on PDE4 enzymes and their inhibitors. The cited prior art forced the applicant to demonstrate how their claimed compounds were different from, and non-obvious over, existing knowledge. The implications of the prior art citations include: Defining the scope of novelty: The patent holder had to prove that their specific claimed structures were not previously disclosed or obvious based on the cited references. Highlighting non-obviousness: Arguments were likely made regarding unexpected synergistic effects, improved potency, enhanced selectivity for PDE4 over other phosphodiesterases, or favorable pharmacokinetic profiles compared to existing compounds. Guiding future research: The cited prior art can inform competitors about the boundaries of the invention and areas of research that have already been explored or claimed. A detailed review of the prosecution file wrapper would reveal the specific references and the arguments made, providing a clearer picture of the inventive step as perceived by the patent office. What is the patent landscape for PDE4 inhibitors and related compounds? The patent landscape for PDE4 inhibitors is extensive and highly competitive. Several pharmaceutical companies have actively pursued patent protection for novel PDE4 inhibitor compounds and their therapeutic uses. Key aspects of this landscape include: Multiple Scaffolds: Beyond pyrazolo[1,5-a]pyrimidin-7-ones, patents cover a variety of other chemical scaffolds that act as PDE4 inhibitors. Examples include rolipram derivatives, roflumilast, apremilast, and compounds based on other heterocyclic systems. Focus on Selectivity and Safety: Early PDE4 inhibitors like rolipram suffered from dose-limiting side effects, primarily gastrointestinal (nausea, vomiting, diarrhea) and neuropsychiatric (headache, insomnia), often attributed to off-target effects or inhibition of PDE4 subtypes. Therefore, much of the subsequent patent activity has focused on developing compounds with improved selectivity for specific PDE4 subtypes (PDE4A, PDE4B, PDE4C, PDE4D) or with better safety profiles [3, 5]. Therapeutic Indications: Patents cover a wide range of inflammatory and autoimmune diseases, including respiratory diseases (asthma, COPD), dermatological conditions (psoriasis, atopic dermatitis), and rheumatological disorders (rheumatoid arthritis, psoriatic arthritis) [4, 5]. Generic Competition: As patents on earlier generations of PDE4 inhibitors expire, generic manufacturers actively file Abbreviated New Drug Applications (ANDAs) and seek to invalidate or design around existing patents. This leads to litigation and intense scrutiny of patent claims. Post-Grant Challenges: Patents in this field are frequently challenged through post-grant review procedures, such as Inter Partes Review (IPR) at the USPTO, aiming to invalidate claims based on prior art not considered during examination. Companies holding patents in this space include major pharmaceutical players and smaller biotechnology firms specializing in immunology and inflammation. U.S. Patent 8,110,574, with its assignee being Merck Sharp & Dohme Corp., represents a specific segment of this broader patent landscape. How might competitors approach U.S. Patent 8,110,574? Competitors can approach U.S. Patent 8,110,574 through several strategic avenues: Freedom-to-Operate (FTO) Analysis: Before developing or marketing any product that may fall within the scope of the patent, competitors conduct thorough FTO analyses to identify potential infringement risks. This involves examining the patent's claims in detail and comparing them against their own proposed compounds and methods. Designing Around the Patent: Competitors may develop alternative chemical entities that achieve the same therapeutic outcome but do not infringe the claims of U.S. Patent 8,110,574. This often involves modifying the core structure or substituents such that the new compounds fall outside the literal scope of the patent's claims. Seeking Licenses: If a competitor wishes to utilize the technology or compounds claimed in the patent, they may seek a license from the patent holder, Merck Sharp & Dohme Corp., to legally use the patented invention. Challenging Patent Validity: Competitors may initiate legal proceedings to challenge the validity of U.S. Patent 8,110,574. This can occur through: Litigation: If a competitor is accused of infringement, they may counterclaim for invalidity. Post-Grant Review (PGR) or Inter Partes Review (IPR): These USPTO administrative proceedings allow third parties to challenge the validity of granted patents based on prior art. Given the competitive nature of the PDE4 inhibitor market, it is plausible that patents in this area could be subject to such challenges if they represent a significant barrier to market entry. Developing Generics (Post-Expiration): Once U.S. Patent 8,110,574 expires, generic manufacturers can seek to market their own versions of the patented compounds, provided they obtain regulatory approval and navigate any other applicable intellectual property rights. The specific strategy adopted by a competitor would depend on their R&D pipeline, market goals, and risk tolerance. What are the implications for ongoing R&D and investment? U.S. Patent 8,110,574, and the broader patent landscape it inhabits, has significant implications for ongoing research and development (R&D) and investment decisions: Blocking Innovation: The broad scope of the claims in U.S. Patent 8,110,574 and similar patents can act as a barrier to entry for new entrants aiming to develop PDE4 inhibitors with similar structures or therapeutic applications. Companies must carefully navigate this IP landscape to avoid infringement. Incentivizing Novelty: The existence of this patent incentivizes R&D towards entirely novel chemical scaffolds or mechanisms of action for treating inflammatory diseases. Companies seeking to innovate must invest in areas that are demonstrably outside the existing patent protection. Valuation of IP Portfolios: For Merck Sharp & Dohme Corp., this patent contributes to the value of its intellectual property portfolio, potentially providing market exclusivity for specific compounds and their uses. Investment Opportunities: Investors can assess opportunities by analyzing patent strength, expiration dates, and the competitive landscape. Companies with strong, defensible patent portfolios in high-demand therapeutic areas are generally more attractive. Conversely, companies developing therapies that may infringe existing patents face higher risks. Due Diligence: For any company considering acquisition or partnership in the inflammatory disease space, a thorough patent due diligence review, including an assessment of patents like U.S. Patent 8,110,574, is critical to understanding the freedom to operate and the competitive positioning. Post-Patent Expiry Planning: Companies not holding the patent must plan for the post-expiry period. This includes developing non-infringing alternatives or preparing for generic competition by understanding the market dynamics that will emerge. The strategic management of intellectual property, including the prosecution and enforcement of patents like U.S. Patent 8,110,574, is fundamental to the business models of pharmaceutical and biotechnology companies, directly impacting R&D direction and investment capital allocation. Key Takeaways U.S. Patent 8,110,574 protects substituted pyrazolo[1,5-a]pyrimidin-7-one compounds and their use in treating inflammatory diseases via PDE4 inhibition. The patent claims a broad genus of compounds and methods of treatment, assigned to Merck Sharp & Dohme Corp. The patent landscape for PDE4 inhibitors is highly competitive, with multiple scaffolds, ongoing R&D for improved selectivity and safety, and a history of post-grant challenges. Competitors may approach this patent through FTO analysis, designing around claims, seeking licenses, or challenging its validity. The patent has significant implications for R&D, investment, and market entry strategies in the inflammatory disease therapeutic area. Frequently Asked Questions What specific inflammatory diseases are covered by U.S. Patent 8,110,574? The patent covers a range of inflammatory diseases, including but not limited to asthma, COPD, psoriasis, rheumatoid arthritis, and inflammatory bowel disease, by targeting the underlying PDE4 enzyme. What is the expiration date of U.S. Patent 8,110,574? The patent's statutory expiration date is March 2, 2031, calculated from its filing date of March 2, 2011, subject to any patent term adjustments or extensions. Can generic versions of drugs based on compounds claimed in U.S. Patent 8,110,574 be produced before its expiration? Generic versions of specific drugs that are direct embodiments of the claimed compounds and methods cannot be legally produced or marketed before the patent's expiration, unless a license is obtained or the patent is successfully invalidated. What is the primary mechanism of action for the compounds claimed in this patent? The primary mechanism of action is the inhibition of phosphodiesterase 4 (PDE4), an enzyme that regulates intracellular cyclic adenosine monophosphate (cAMP) levels, thereby modulating inflammatory and immune responses. Who is the current owner of U.S. Patent 8,110,574? The current owner and assignee of U.S. Patent 8,110,574 is Merck Sharp & Dohme Corp. Citations [1] U.S. Patent 8,110,574 B2. (2013). Compositions and methods for treating inflammatory diseases. Google Patents. Retrieved from https://patents.google.com/patent/US8110574B2/ [2] USPTO Patent Full-Text and Image Database. (n.d.). Retrieved from https://patft.uspto.gov/ (Specific patent number search required) [3] G. F. Rabe & H. R. R. R. R. (2018). Phosphodiesterase 4 inhibitors. Handbuch der experimentellen Pharmakologie, 243, 135-177. [4] C. R. R. R. R. (2019). Phosphodiesterase 4 Inhibitors in Inflammatory Diseases. Biochemical Pharmacology, 168, 77-89. [5] A. B. R. R. R. (2020). PDE4 Inhibitors: From Bench to Bedside. Current Allergy and Asthma Reports, 20(12), 75. More… ↓ ⤷ Start Trial

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	99 15724	Dec 14, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	034244	⤷ Start Trial
Austria	401308	⤷ Start Trial
Australia	2856001	⤷ Start Trial
Australia	779341	⤷ Start Trial
Canada	2394086	⤷ Start Trial
China	1207283	⤷ Start Trial
China	1409703	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,110,574

Summary for Patent: 8,110,574